Bal Miriam P, de Vries Willem B, van Oosterhout Matthijs F M, Baan Jan, van der Wall Ernst E, van Bel Frank, Steendijk Paul
Department of Cardiology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
J Appl Physiol (1985). 2008 Feb;104(2):446-50. doi: 10.1152/japplphysiol.00951.2007. Epub 2007 Dec 13.
Dexamethasone is clinically applied in preterm infants to treat or prevent chronic lung disease. However, concern has emerged about adverse side effects. The cardiovascular short-term side effects of neonatal dexamethasone treatment are well documented, but long-term consequences are unknown. Previous studies showed suppressed mitosis during dexamethasone treatment, leading to reduced ventricular weight, depressed systolic function, and compensatory dilatation in prepubertal rats. In addition, recent data indicated a reduced life expectancy. Therefore, we investigated the long-term effects of neonatal dexamethasone treatment on cardiovascular function. Neonatal rats were treated with dexamethasone or received saline. Cardiac function was determined in 8-, 50-, and 80-wk-old animals, representing young adult, middle-aged, and elderly stages. A pressure-conductance catheter was introduced into the left ventricle to measure pressure-volume loops. Subsequently, the hearts were collected for histological examination. Our results showed reduced ventricular and body weights in dexamethasone-treated rats at 8 and 80 wk, but not at 50 wk. Cardiac output and diastolic function were unchanged, but systolic function was depressed at 50 and 80 wk, evidenced by reduced ejection fractions and rightward shifts of the end-systolic pressure-volume relationships. We concluded that previously demonstrated early adverse effects of neonatal dexamethasone treatment are transient but that reduced ventricular weight and systolic dysfunction become manifest again in elderly rats. Presumably, cellular hypertrophy initially compensates for the dexamethasone treatment-induced lower number of cardiomyocytes, but this mechanism falls short at a later stage, leading to systolic dysfunction. If applicable to humans, cardiac screening of a relatively large patient group to enable secondary prevention may be indicated.
地塞米松在临床上用于治疗或预防早产儿慢性肺病。然而,人们已开始关注其不良副作用。新生儿地塞米松治疗的心血管短期副作用已有充分记录,但长期后果尚不清楚。先前的研究表明,地塞米松治疗期间有丝分裂受到抑制,导致青春期前大鼠心室重量减轻、收缩功能降低和代偿性扩张。此外,最近的数据表明预期寿命缩短。因此,我们研究了新生儿地塞米松治疗对心血管功能的长期影响。对新生大鼠给予地塞米松治疗或生理盐水。在8周、50周和80周龄的动物(分别代表年轻成年、中年和老年阶段)中测定心脏功能。将压力-导纳导管插入左心室以测量压力-容积环。随后,收集心脏进行组织学检查。我们的结果显示,地塞米松治疗组大鼠在8周和80周时心室和体重减轻,但在50周时没有。心输出量和舒张功能未改变,但在50周和80周时收缩功能降低,表现为射血分数降低和收缩末期压力-容积关系右移。我们得出结论,先前证明的新生儿地塞米松治疗的早期不良影响是短暂的,但心室重量减轻和收缩功能障碍在老年大鼠中再次显现。推测细胞肥大最初可补偿地塞米松治疗引起的心肌细胞数量减少,但这种机制在后期失效,导致收缩功能障碍。如果适用于人类,可能需要对相对较大的患者群体进行心脏筛查以进行二级预防。